Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 8Colorectal Neoplasms 6Rectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Wilms Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic to Liver 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Metastatic Gastric Adenocarcinoma 1Malignant Ascites 1Locally Advanced Rectal Cancer 1Hepatoblastoma 1Gastroesophageal Junction Adenocarcinoma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1

Interventions

X-Rays 2Vincristine 2Temozolomide 2Specimen Handling 2Phantoms, Imaging 2Irinotecan 2Etoposide 2Cyclophosphamide 2talazoparib 1selinexor 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1cabozantinib 1atezolizumab 1Vorinostat 1Topotecan 1Surgical Procedures, Operative 1Radiotherapy 1Radiation 1Proton Therapy 1Platinum 1Mesna 1Magnetic Resonance Spectroscopy 1Isotretinoin 1Ifosfamide 1Doxorubicin 1Data Collection 1Carboplatin 1Bone Density 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Wilms Tumor × irinotecan sucrosofate × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡